Bradford A Perez

Dr. Bradford A Perez


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2017 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
KAKamran A. Ahmed
Kamran A. Ahmed
SKSungjune Kim
Sungjune Kim
JAJohn Arrington
John Arrington
ANArash O. Naghavi
Arash O. Naghavi
TDThomas J. Dilling
Thomas J. Dilling
BPBradford A Perez
Bradford A Perez

30 December 2013 in Cancer
Verified
Journal Article
Open access
PDF file
JKJohn P. Kirkpatrick
John P. Kirkpatrick
CKChristopher R. Kelsey
Christopher R. Kelsey
MPManisha Palta
Manisha Palta
ACAlvin R. Cabrera
Alvin R. Cabrera
JSJoseph Kamel Salama
Joseph Kamel Salama
FYFang‐Fang Yin
Fang‐Fang Yin
Stereotactic body radiotherapy (SBRT) involves the treatment of extracranial primary tumors or metastases with a few, high doses of ionizing radiation. In SBRT, tumor kill is maximized and dose to surrounding tissue is minimized, by precise and accurate delivery of multiple radiation beams to the target. This is particularly challenging, because extracranial lesions often move with respiration and are irregular in shape, requiring careful treatment planning and continual management of this motion and patient position during irradiation. This review presents the rationale, process workflow, and technology for the safe and effective administration of SBRT, as well as the indications, outcome, and limitations for this technique in the treatment of lung cancer, liver cancer, and metastatic disease. Cancer 2014;120:942–954. © 2013 American Cancer Society.

28 September 2020 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
BPBradford A Perez
Bradford A Perez
SKSungjune Kim
Sungjune Kim
MWMinhsuan Wang
Minhsuan Wang
AKAhmad M. Karimi
Ahmad M. Karimi
CPChase Powell
Chase Powell
SAScott J. Antonia
Scott J. Antonia

1 September 2017 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
ZYZhigang Yuan
Zhigang Yuan
AFAllison Fromm
Allison Fromm
KAKamran A. Ahmed
Kamran A. Ahmed
GGGeorge D. Grass
George D. Grass
GYGeorge Q. Yang
George Q. Yang
BPBradford A Perez
Bradford A Perez

2 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
AMAlexandra L. Martin
Alexandra L. Martin
CACarmen Anadon
Carmen Anadon
SBSubir Biswas
Subir Biswas
JMJessica A. Mine
Jessica A. Mine
KHKatelyn F. Handley
Katelyn F. Handley
JCJose R Conejo-Garcia
Jose R Conejo-Garcia
Although chimeric antigen receptor (CAR)-expressing T cells have proven success in hematologic malignancies, their effectiveness in solid tumors has been largely unsuccessful thus far. We found that some olfactory receptors are expressed in a variety of solid tumors of different histologic subtypes, with a limited pattern of expression in normal tissues. Quantification of OR2H1 expression by qRT-PCR and Western blot analysis of 17 normal tissues, 82 ovarian cancers of various histologies, eight non–small cell lung cancers (NSCLCs), and 17 breast cancers demonstrated widespread OR2H1 expression in solid epithelial tumors with expression in normal human tissues limited to the testis. CAR T cells recognizing the extracellular domain of the olfactory receptor OR2H1 were generated with a targeting motif identified through the screening of a phage display library and demonstrated OR2H1-specific cytotoxic killing in vitro and in vivo, using tumor cells with spontaneous expression of variable OR2H1 levels. Importantly, recombinant OR2H1 IgG generated with the VH/VL sequences of the CAR construct specifically detected OR2H1 protein signal in 60 human lung cancers, 40 ovarian carcinomas, and 73 cholangiocarcinomas, at positivity rates comparable with mRNA expression and without OR2H1 staining in 58 normal tissues. CRISPR/Cas9-mediated ablation of OR2H1 confirmed targeting specificity of the CAR and the tumor-promoting role of OR2H1 in glucose metabolism. Therefore, T cells redirected against OR2H1-expressing tumor cells represent a promising therapy against a broad range of epithelial cancers, likely with an admissible toxicity profile.

3 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JPJaya Padmanabhan
Jaya Padmanabhan
Biswarup SahaBiswarup Saha
Biswarup Saha
CPChase Powell
Chase Powell
QMQIANXING MO
QIANXING MO
BPBradford A Perez
Bradford A Perez
SCSrikumar Chellappan
Srikumar Chellappan
Non-small cell lung cancer has a 5-year survival rate of less than 12–15%, calling for the development of additional therapeutic strategies to combat this disease. Here we tested the efficacy of inhibiting cyclin-dependent kinase 9 (CDK9) on lung cancer cell lines with K-Ras and EGFR mutations and on lung cancer organoids. Three different CDK9 inhibitors reduced the viability and anchorage-independent growth of lung cancer cell lines at very low nanomolar to micromolar concentrations. CDK9 inhibition suppressed the expression of the anti-apoptotic protein, Mcl1, as well as the embryonic stem cell transcription factors, Sox2 and Sox9, which are pro-tumorigenic. In contrast, treatment with CDK9 inhibitors increased the levels of WT p53 and its downstream target p21 in K-Ras mutant cell lines. Furthermore, the CDK9 inhibitors could markedly reduce the viability of Osimertinib-resistant PC9 and AMG510-resistant H23 and H358 cells with comparable efficacy as the parental cells. CDK9 inhibitors could also significantly reduce the growth and viability of lung cancer organoids with high potency. Taken together, the data presented here strongly suggest that CDK9 inhibitors would be efficacious against K-Ras mutant and EGFR mutant NSCLCs, including those that develop resistance to targeted therapies.